NCT07074327CompletedPhase 1
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
Phase 1, Open-label Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Subjects
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 74 (actual)
- First submitted
- 9 Jul 2025
- Start date
- 11 Jul 2025
- Primary completion date
- 20 Feb 2026
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Diseases
- Polycystic kidney disease
- NCT number
- NCT07074327
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 74
- From 11 Jul 2025 to the primary completion date, 20 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of febrile illness within 5 days before the first dose of study drug
- Relative contraindications to hormonal estrogen therapy that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant
- Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of study drug
- Previously received study drug in this study
- Other protocol defined Inclusion/Exclusion criteria may apply.
Other illness
- Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
Other
- Menopausal, post-menopausal, or documented bilateral oophorectomy and/or hysterectomy
Who the study is looking for
- Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m\^2)
- A total body weight of greater than (\>) 50 kg
- Nonsmoker or ex-smoker for at least 12 months before screening
- Oral contraceptive naïve or able to comply with 28-day or 5 half-lives (whichever is greater) washout before the start of Period 1 (6-month washout for Depo-Provera)
Age in the registry: 18 years to 50 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Altasciences - Kansas City Coordinator of this site? Confirm its status | Overland Park | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.